Compare JBSS & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBSS | MNKD |
|---|---|---|
| Founded | 1959 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.1M | 793.6M |
| IPO Year | 1994 | 2004 |
| Metric | JBSS | MNKD |
|---|---|---|
| Price | $81.51 | $2.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $109.00 | $8.56 |
| AVG Volume (30 Days) | 56.1K | ★ 4.6M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.12 | 0.02 |
| Revenue | ★ $1,107,246,000.00 | $348,966,000.00 |
| Revenue This Year | $5.58 | $35.81 |
| Revenue Next Year | N/A | $11.89 |
| P/E Ratio | ★ $25.79 | $131.75 |
| Revenue Growth | 3.79 | ★ 22.23 |
| 52 Week Low | $59.07 | $2.23 |
| 52 Week High | $85.15 | $6.51 |
| Indicator | JBSS | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 56.24 | 45.21 |
| Support Level | $61.12 | $2.52 |
| Resistance Level | $81.93 | $4.09 |
| Average True Range (ATR) | 2.53 | 0.12 |
| MACD | 0.23 | 0.12 |
| Stochastic Oscillator | 66.89 | 97.09 |
John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.